Results 121 to 130 of about 655,557 (182)

Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. [PDF]

Cancer Chemother Pharmacol
Bell R, O'Brien LM, Yuen E, Liu D, Chapman SC.   +4 more
europepmc   +1 more source

Efficacy and safety analysis of a novel BTK inhibitor in patients with mantle cell lymphoma harboring TP53 mutations. [PDF]

Am J Cancer Res
Liu M, Ding Y, Lan H.
europepmc   +1 more source

Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. [PDF]

Cancer
Zhang J, Luo J, Shen X, Ren J, Liu W, Chen L, Jiang L, Weng X, Wang J, Mi JQ.   +9 more
europepmc   +1 more source

Another step toward frontline BTK inhibitor therapy in MCL. [PDF]

Blood Adv, 2023
Hanel W, Epperla N.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study. [PDF]

Blood Adv
Autore F, Tedeschi A, Benevolo G, Danesin N, Giannarelli D, Rizzi R, Cencini E, Mattiello V, Ferrarini I, Pasquale R, Del Giudice I, Ferrari A, Bullo M, Rossini B, Motta M, Marino D, Innocenti I, Stirparo L, Petrilli D, Musto P, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L.   +26 more
europepmc   +1 more source

Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895. [PDF]

Cancer Res Commun
Stromatt JC, Ahmed EA, Drabison T, Nepal MR, Chowdhury AT, Orwick SJ, Buelow DR, Eisenmann ED, Huang KM, Sparreboom A, Baker SD.   +10 more
europepmc   +1 more source

Bing-Neel Syndrome in Waldenström Macroglobulinemia: Updates on Clinical Management and BTK Inhibitor Efficacy. [PDF]

Cancers (Basel)
Saburi M, Sekiguchi N.
europepmc   +1 more source

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. [PDF]

Blood Cancer J
Timofeeva N, Herrera B, Fujiwara H, Asami T, Endo H, Hatakeyama M, Nakajima F, Ohmoto H, Nishioka Y, Miyamoto K, Arimura A, Tantawy SI, Pinilla-Ibarz J, Coombs CC, Jain N, Sawa M, Gandhi V.   +16 more
europepmc   +1 more source

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia. [PDF]

Ann Med
Xia Y, Shen H, Miao Y, Zhao Y, Liu H, Wang S, Tian T, Xu J, Qu X, Li J, Fan L.   +10 more
europepmc   +1 more source